Quantum Biopharma Ltd.(QNTM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

QNTM Quantum Biopharma Ltd.

Market Closed 05-01 16:00:00 EDT

5.55

-0.18

-3.14%

盘后5.55

+0.00+0.06%

19:16 EDT

High6.16	Low5.39	Vol360.01K
Open5.73	D1 Closing5.73	Amplitude13.46%
Mkt Cap32.35M	Tradable Cap29.12M	Total Shares5.83M
T/O2.09M	T/O Rate6.86%	Tradable Shares5.25M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"QNTM","market":"US","secType":"STK","nameCN":"Quantum Biopharma Ltd.","latestPrice":5.55,"timestamp":1777665600000,"preClose":5.73,"halted":0,"volume":360008,"hourTrading":{"tag":"盘后","latestPrice":5.5534,"preClose":5.55,"latestTime":"19:16 EDT","volume":18600,"amount":100743.9428,"timestamp":1777677407036,"change":0.0034,"changeRate":0.000613,"amplitude":0.029441},"delay":0,"changeRate":-0.03141361256544513,"floatShares":5247700,"shares":5829299,"eps":-7.965999,"marketStatus":"Market Closed","change":-0.18,"latestTime":"05-01 16:00:00 EDT","open":5.73,"high":6.1586,"low":5.3872,"amount":2085016.5726720002,"amplitude":0.134625,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-7.965999,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1777881600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":5.73,"preHourTrading":{"tag":"盘前","latestPrice":5.81,"preClose":5.73,"latestTime":"09:23 EDT","volume":1418,"amount":8248.4687066,"timestamp":1777641818786,"change":0.08,"changeRate":0.013962,"amplitude":0.104712},"postHourTrading":{"tag":"盘后","latestPrice":5.5534,"preClose":5.55,"latestTime":"19:16 EDT","volume":18600,"amount":100743.9428,"timestamp":1777677407036,"change":0.0034,"changeRate":0.000613,"amplitude":0.029441},"volumeRatio":0.418052},"requestUrl":"/m/hq/s/QNTM/tweets","defaultTab":"tweets","newsList":[{"id":"2630034960","title":"Quantum BioPharma Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2630034960","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630034960?lang=en_us&edition=fundamental","pubTime":"2026-04-28 07:45","pubTimestamp":1777333500,"startTime":"0","endTime":"0","summary":"THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, April  27, 2026 (G","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/27/3282159/0/en/Quantum-BioPharma-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNTM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629044923","title":"Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant","url":"https://stock-news.laohu8.com/highlight/detail?id=2629044923","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629044923?lang=en_us&edition=fundamental","pubTime":"2026-04-22 21:16","pubTimestamp":1776863760,"startTime":"0","endTime":"0","summary":"TORONTO, April  22, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innov","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/22/3279059/0/en/Quantum-BioPharma-Licensee-Unbuzzd-Wellness-Inc-Appoints-Richard-Buzbuzian-as-CEO-to-Lead-Nationwide-Commercialization-of-Innovative-Clinically-Validated-Hangover-Remedy-and-Alcoho.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DBB","BK4007","QNTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624509776","title":"Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied","url":"https://stock-news.laohu8.com/highlight/detail?id=2624509776","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624509776?lang=en_us&edition=fundamental","pubTime":"2026-04-02 20:30","pubTimestamp":1775133000,"startTime":"0","endTime":"0","summary":"TORONTO, April  02, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a p","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/02/3267341/0/en/Quantum-BioPharma-Wins-Significant-Court-Challenge-in-USD-700-000-000-Claim-as-Defendants-Joint-Motion-to-Dismiss-Lawsuit-Alleging-Market-Manipulation-by-CIBC-World-Markets-and-RBC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JYNT","USD","BK4185","BK4007","QNTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624139145","title":"Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2624139145","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624139145?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:02","pubTimestamp":1775044920,"startTime":"0","endTime":"0","summary":"TORONTO, April  01, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/01/3266579/0/en/Quantum-BioPharma-Submits-Investigational-New-Drug-IND-Application-to-United-States-Food-and-Drug-Administration-FDA-for-Lucid-MS-Phase-Two-Clinical-Trial-in-Multiple-Sclerosis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKVL7J92.USD","LCID","LU0006306889.USD","LU2271345857.HKD","LU0795875169.SGD","LU1162221912.USD","BK4516","BK4555","LU0098860793.USD","LU1720051108.HKD","LU0267386448.USD","LCDL","BK4551","LU1244550577.SGD","LU1791710400.SGD","BK4007","LU0557290698.USD","LU2028103732.USD","LU2357305700.SGD","BK4099","QNTM","IND","LU0158827948.USD","LU0225283273.USD","LU0320765646.SGD","LU2089283258.USD","LU1720051017.SGD","BK4127","LU0158827781.USD","LCIZ","LU2347655156.SGD","BK4588","LU2089284900.SGD","LU1244550494.USD","LU2133065610.SGD","UBCP","BK4534","LU0106261372.USD","BK4504","LU0314104364.USD","LU0795875086.SGD","LU1074936037.SGD","LU1363072403.SGD","LU0528227936.USD","BK4581","LU0882574139.USD","LU2111349929.HKD","LABU","LU1989772840.SGD","BK4596"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623426883","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 11:50 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2623426883","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623426883?lang=en_us&edition=fundamental","pubTime":"2026-03-30 23:50","pubTimestamp":1774885810,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 11:50 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nAQN2LSHLS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNTM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623312918","title":"Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2623312918","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623312918?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:50","pubTimestamp":1774871400,"startTime":"0","endTime":"0","summary":"Strategic Partnership with Global Clinical Research Organization (CRO) Signifies Advancement in Clinical Development of Lucid-21-302 (Lucid-MS), a Novel First-in-Class Treatment Inhibiting Demyelinati","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/30/3264540/0/en/Quantum-BioPharma-Signs-Binding-Letter-Of-Intent-With-Allucent-To-Conduct-Phase-2-Clinical-Trial-In-Multiple-Sclerosis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0528227936.USD","LCIZ","IE00BKVL7J92.USD","LU0912757837.SGD","BK4516","LU1244550577.SGD","LU2357305700.SGD","BK4534","LU2028103732.USD","BK4555","LU0795875169.SGD","BK4127","LU1989772840.SGD","LU2133065610.SGD","LU1244550494.USD","LU2111349929.HKD","IE00BZ1G4Q59.USD","LU0098860793.USD","LU0006306889.USD","LU0320765646.SGD","LU0106831901.USD","LU1548497426.USD","LU0267386448.USD","BK4585","LU0158827781.USD","BK4007","LU1720051108.HKD","LU0106261372.USD","LU0557290698.USD","LCDL","BK4551","LCID","LU0971096721.USD","LU1162221912.USD","LU2271345857.HKD","LU0234570918.USD","LU1720051017.SGD","BK4581","LU1732799900.SGD","LU2089284900.SGD","QNTM","LU0314104364.USD","LU0882574139.USD","LU1791710400.SGD","LU1668664300.SGD","LU2023251221.USD","LU1244550221.USD","BK4099","BK4504","LU0795875086.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622680809","title":"Quantum Biopharma Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2622680809","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622680809?lang=en_us&edition=fundamental","pubTime":"2026-03-28 07:30","pubTimestamp":1774654200,"startTime":"0","endTime":"0","summary":"THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, March  27, 2026 (G","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/27/3264151/0/en/Quantum-Biopharma-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","QNTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622829829","title":"Press Release: Quantum Biopharma's 2025 Audited Year End Financial Results Maintain 'No Going Concern' Status","url":"https://stock-news.laohu8.com/highlight/detail?id=2622829829","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622829829?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:10","pubTimestamp":1774613400,"startTime":"0","endTime":"0","summary":"Multiple Sclerosis Drug Candidate Lucid-21-302 Phase 1 Trial with Toxicology Studies Complete, and unbuzzd Clinical Trial Published in Peer-Reviewed Journal. TORONTO, March 27, 2026  -- Quantum BioPharma Ltd.    , has reported its audited financial and operational results for the fourth quarter and year ended December 31, 2025.Fourth Quarter and Full Year 2025 Financial Results. For the year ended December 31, 2025, Operating Expenses were reduced to $15.3 million USD compared to $16.1 million USD in the same period of 2024, an improvement of approximately 5%.For the year ended December 31, 2025, external research and development fees decreased to $2.8 million USD compared to $6.1 million USD in the same period of 2024 as a result of phase 1 clinical trials ending, as well as R&D tax credit initiatives provided by the Australian government during FY2025.unbuzzd Peer Review Journal Publication of Positive Game Changing Results","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720051108.HKD","LCID","LU0912757837.SGD","LU1668664300.SGD","BK4534","USD","LU1791710400.SGD","LU0320765646.SGD","LU0528227936.USD","LU2111349929.HKD","LU1162221912.USD","LU1363072403.SGD","TM","BK4099","LU2347655156.SGD","LU2357305700.SGD","QNTM","LCDL","LU1989772923.USD","LU0158827948.USD","LU1244550577.SGD","LU0006306889.USD","LU1244550494.USD","LU1989772840.SGD","LCIZ","BK4585","LU0971096721.USD","LU1720051017.SGD","LU2023251221.USD","LU0795875169.SGD","BK4007","BK4596","BK4588","LU0234570918.USD","LU0106831901.USD","BK4604","BK4551","LU0882574139.USD","LU0225283273.USD","IE00BKVL7J92.USD","LU0557290698.USD","03160","LU0098860793.USD","LU0158827781.USD","LU2089283258.USD","LU0795875086.SGD","LU1732799900.SGD","IPO","LU2028103732.USD","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622189418","title":"Quantum BioPharma Q4 EPS $(0.71) Beats $(0.93) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2622189418","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622189418?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:58","pubTimestamp":1774562337,"startTime":"0","endTime":"0","summary":"Quantum BioPharma (NASDAQ:QNTM) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.93) by 23.66 percent. This is a 65.53 percent increase over losses of $(2.06) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51498487/quantum-biopharma-q4-eps-0-71-beats-0-93-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Quantum BioPharma Q4 EPS $(0.71) Beats $(0.93) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","QNTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622850394","title":"Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2622850394","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622850394?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:00","pubTimestamp":1774526400,"startTime":"0","endTime":"0","summary":"Highlights advancement of first-in-class neuroprotective candidate targeting demyelinationTORONTO, March  26, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Q","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/26/3262941/0/en/Quantum-Biopharma-Announces-Appointment-of-Principal-Investigator-for-Planned-Phase-2-Clinical-Trial-of-Lucid-21-302-Lucid-MS-in-Multiple-Sclerosis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","BK4596","LU0098860793.USD","BK4162","LU0882574139.USD","LU2028103732.USD","LU1244550494.USD","LU1244550577.SGD","LU2089283258.USD","LCDL","LU0106261372.USD","PFG","IND","BK4099","LU0234570918.USD","LU0006306889.USD","LU1732799900.SGD","LU1989772840.SGD","BK4007","LU1548497426.USD","BK4588","LU0106831901.USD","BK4127","LU0912757837.SGD","LU1791710400.SGD","LU2271345857.HKD","LU0158827781.USD","LU0557290698.USD","LU0314104364.USD","QNTM","LU1989772923.USD","LU1720051017.SGD","LU2111349929.HKD","LU1720051108.HKD","LU1791710582.SGD","BK4516","IE00BKVL7J92.USD","LU0795875169.SGD","LU2023251221.USD","LU2357305700.SGD","LU1162221912.USD","LU0267386448.USD","LU1732800096.USD","LU2089284900.SGD","LU0320765646.SGD","LU0795875086.SGD","LU0971096721.USD","LU0225283273.USD","LCIZ","LCID"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621703060","title":"Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd","url":"https://stock-news.laohu8.com/highlight/detail?id=2621703060","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621703060?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:24","pubTimestamp":1774268640,"startTime":"0","endTime":"0","summary":"unbuzzd Dramatically Accelerates Alcohol Metabolism, Speeds the Reduction of Blood Alcohol Concentration, and Reduces Symptoms of Intoxication, Impairment and HangoverTORONTO, March  23, 2026 (GLOBE N","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/23/3260361/0/en/Quantum-BioPharma-Announces-Peer-Reviewed-Journal-Publication-of-Groundbreaking-Clinical-Trial-With-Unbuzzd.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0001KFT4U8.USD","IE00B7SZLL34.SGD","IE0034235188.USD","LU0053666078.USD","LU0203347892.USD","LU0868494617.USD","LU1035773651.USD","LU1201861165.SGD","LU1496350502.SGD","IE00BZ1G4Q59.USD","LU0098860793.USD","LU1506573853.SGD","LU1718418525.SGD","BK4007","LU0306807586.USD","IE00B19Z3B42.SGD","LU0683600562.USD","BAC","BK4585","LU0149725797.USD","LU0477156797.USD","LU1267930227.SGD","LU1162221912.USD","LU0130518102.USD","IE00B1BXHZ80.USD","LU1366192091.USD","LU1894683348.USD","LU1069347547.HKD","LU0106831901.USD","LU0211331839.USD","LU0130517989.USD","IE00BLSP4452.SGD","BK4559","LU0070302665.USD","LU0320765646.SGD","LU0648001328.SGD","LU0256863902.USD","LU0130102774.USD","LU0128525689.USD","LU1880398554.USD","IE00B19Z3581.USD","LU0787776722.HKD","LU0980610538.SGD","LU0321505439.SGD","LU1496350171.SGD","IE0002270589.USD","LU0234570918.USD","QNTM","LU0321505868.SGD","LU1883839398.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621750588","title":"Press Release: Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2621750588","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621750588?lang=en_us&edition=fundamental","pubTime":"2026-03-21 07:35","pubTimestamp":1774049700,"startTime":"0","endTime":"0","summary":"THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.TORONTO, March 20, 2026  -- Quantum BioPharma Ltd.    , is pleased to announce that it has closed an initial tranche  of the offering announced on March 10, 2026 and March 11, 2026  and has issued 3,750 Debenture Units  for $3,750,000.The Company will use the proceeds from the First Tranche for the ongoing development of the Company's business model and for general working capital purposes.The participation by insiders of the Company in the Debt Settlement constitutes a \"related party transaction\" as defined under Multilateral Instrument 61-101 -- Protection of Minority Security Holders in Special Transactions . The Company is relying on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5 and 5.7 of MI 61-101, as neither the fair market value ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TM","QNTM","03160","BK4604","BK4555","BK4099","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618972177","title":"Quantum BioPharma Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2618972177","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618972177?lang=en_us&edition=fundamental","pubTime":"2026-03-12 07:55","pubTimestamp":1773273300,"startTime":"0","endTime":"0","summary":"THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, March  11, 2026 (G","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/11/3254229/0/en/Quantum-BioPharma-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","QNTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618960153","title":"Quantum BioPharma Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2618960153","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618960153?lang=en_us&edition=fundamental","pubTime":"2026-03-11 07:45","pubTimestamp":1773186300,"startTime":"0","endTime":"0","summary":"THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FORDISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, March  10, 2026  (G","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/10/3253449/0/en/Quantum-BioPharma-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","QNTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593541883","title":"Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2593541883","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593541883?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:00","pubTimestamp":1766494800,"startTime":"0","endTime":"0","summary":"Studies Will Support Investigational New Drug Application (IND) with the US FDA, Including Design of Phase 2 TrialTORONTO, Dec.  23, 2025  (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/23/3209828/0/en/Quantum-Biopharma-Announces-Completion-of-Dosing-in-180-Day-Repeated-Dose-Oral-Toxicity-and-Toxicokinetic-Studies-for-Lucid-21-302-Lucid-MS.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2089283258.USD","LU2133065610.SGD","LU1732799900.SGD","LU0106831901.USD","LU2089284900.SGD","LU0158827948.USD","LU0528227936.USD","LU1989772923.USD","LU0795875169.SGD","LU0795875086.SGD","BK4099","LU0234570918.USD","BK4585","IE00BZ1G4Q59.USD","LU1989772840.SGD","LU1548497426.USD","LU2271345857.HKD","BK4555","BK4581","LU0971096721.USD","LU0314104364.USD","LU0158827781.USD","LU1668664300.SGD","LU0557290698.USD","LU0320765646.SGD","LU0006306889.USD","IE00BKVL7J92.USD","LU0267386448.USD","LU0098860793.USD","QNTM","LU1244550494.USD","BK4596","LU0912757837.SGD","LU1720051108.HKD","LU2357305700.SGD","IND","LU0882574139.USD","LU1363072403.SGD","LU1162221912.USD","BK4534","LU1244550577.SGD","LU2111349929.HKD","BK4516","BK4127","LU1244550221.USD","LU1791710400.SGD","LU1732800096.USD","BK4551","LCID"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592382113","title":"World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592382113","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592382113?lang=en_us&edition=fundamental","pubTime":"2025-12-20 05:52","pubTimestamp":1766181120,"startTime":"0","endTime":"0","summary":"TORONTO, Dec.  19, 2025  (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), understands that Quantum BioPharma shareholder Paul Durkacz has filed ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/19/3208756/0/en/World-Renowned-Law-Firm-Grant-Eisenhofer-Files-Class-Action-Lawsuit-Against-Canadian-Banks-CIBC-and-RBC-Alleging-Illegal-Stock-Market-Manipulation-of-Quantum-BioPharma-Shares.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNTM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588223607","title":"Investigative News Program W5 Airs Final Segment on USD $700 Million Stock Market Manipulation Lawsuit of Quantum Biopharma Involving CIBC and RBC","url":"https://stock-news.laohu8.com/highlight/detail?id=2588223607","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588223607?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590400,"startTime":"0","endTime":"0","summary":"TORONTO, Dec.  01, 2025  (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), is pleased to announce that national television network CTV News’ flag","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/01/3196861/0/en/Investigative-News-Program-W5-Airs-Final-Segment-on-USD-700-Million-Stock-Market-Manipulation-Lawsuit-of-Quantum-Biopharma-Involving-CIBC-and-RBC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4516","LU1989772840.SGD","LU1244550221.USD","LU0225283273.USD","LU0971096721.USD","LU1244550577.SGD","LU0795875086.SGD","LU1074936037.SGD","LU0106831901.USD","LU1668664300.SGD","IE00BZ1G4Q59.USD","LU1732800096.USD","LU0106261372.USD","LU1732799900.SGD","BK4534","LU1244550494.USD","LU2133065610.SGD","IE00BKVL7J92.USD","LU2347655156.SGD","BK4585","LU0098860793.USD","LU2028103732.USD","BK4504","LU2023251221.USD","LU2111349929.HKD","BK4127","BK4588","LU2089283258.USD","LU0795875169.SGD","LU2271345857.HKD","BK4007","LU0557290698.USD","LU0882574139.USD","LU0912757837.SGD","LU0158827948.USD","LU1791710400.SGD","LU1162221912.USD","LU0006306889.USD","LU1548497426.USD","LU2357305700.SGD","LU0320765646.SGD","LU0314104364.USD","LU1363072403.SGD","LU1791710582.SGD","BK4581","QNTM","USD","LU0267386448.USD","LU1720051017.SGD","LU2089284900.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586022084","title":"Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBC","url":"https://stock-news.laohu8.com/highlight/detail?id=2586022084","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586022084?lang=en_us&edition=fundamental","pubTime":"2025-11-28 05:00","pubTimestamp":1764277200,"startTime":"0","endTime":"0","summary":"TORONTO, Nov.  27, 2025  (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), is pleased to announce that national television network CTV News’ flag","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/27/3195939/0/en/Award-winning-Investigative-News-Program-W5-Airs-Part-2-of-3-part-Television-Series-on-Alleged-Stock-Market-Manipulation-of-Quantum-Biopharma-Involving-Two-of-Canada-s-Largest-Bank.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4099","BK4596","LCID","BK4555","QNTM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586840601","title":"Quantum Biopharma’s USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5","url":"https://stock-news.laohu8.com/highlight/detail?id=2586840601","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586840601?lang=en_us&edition=fundamental","pubTime":"2025-11-26 05:00","pubTimestamp":1764104400,"startTime":"0","endTime":"0","summary":"TORONTO, Nov.  25, 2025   -- Quantum BioPharma Ltd.    , is pleased to announce that national television network CTV News’ flagship investigative program W5 will air, starting today, a three-part series about Quantum Biopharma and the company’s allegations of stock market manipulation. Top CTV News journalist and W5 investigative reporter Jon Woodward describes Part One of the series in an article entitled, “Was a Canadian company’s multiple sclerosis research nearly derailed by ‘market manipulation’?”","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/25/3194699/0/en/Quantum-Biopharma-s-USD-700-Million-Lawsuit-Alleging-Stock-Market-Manipulation-Subject-of-3-part-Series-Investigative-News-Program-W5.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4596","QNTM","BK4099","BK4555","USD","LCID","BK4007","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2581004834","title":"Quantum Biopharma Ltd  expected to post a loss of 22 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581004834","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581004834?lang=en_us&edition=fundamental","pubTime":"2025-11-08 06:11","pubTimestamp":1762553467,"startTime":"0","endTime":"0","summary":"Quantum Biopharma Ltd  expected to post a loss of22cents a share - Earnings Preview Quantum Biopharma Ltd QNTM.CD  is expected to  show a rise in quarterly revenue when it reports  results on November","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ306:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","QNTM"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.quantumbiopharma.com","stockEarnings":[{"period":"1week","weight":0.5374},{"period":"1month","weight":0.2585},{"period":"3month","weight":0.2118},{"period":"6month","weight":-0.4986},{"period":"1year","weight":-0.1838},{"period":"ytd","weight":-0.2397}],"compareEarnings":[{"period":"1week","weight":0.0094},{"period":"1month","weight":0.0998},{"period":"3month","weight":0.0414},{"period":"6month","weight":0.0566},{"period":"1year","weight":0.2904},{"period":"ytd","weight":0.0568}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.01855},{"month":2,"riseRate":0.714286,"avgChangeRate":0.114242},{"month":3,"riseRate":0.285714,"avgChangeRate":0.061101},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.067135},{"month":5,"riseRate":0.142857,"avgChangeRate":0.050765},{"month":6,"riseRate":0.5,"avgChangeRate":0.033021},{"month":7,"riseRate":0.666667,"avgChangeRate":-0.017895},{"month":8,"riseRate":0.5,"avgChangeRate":-0.092936},{"month":9,"riseRate":0,"avgChangeRate":-0.105415},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.136125},{"month":11,"riseRate":0.333333,"avgChangeRate":0.040234},{"month":12,"riseRate":0,"avgChangeRate":-0.179121}],"exchange":"NASDAQ","name":"Quantum Biopharma Ltd.","nameEN":"Quantum Biopharma Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Quantum Biopharma Ltd.(QNTM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Quantum Biopharma Ltd.(QNTM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Quantum Biopharma Ltd.,QNTM,Quantum Biopharma Ltd.股票,Quantum Biopharma Ltd.股票老虎,Quantum Biopharma Ltd.股票老虎国际,Quantum Biopharma Ltd.行情,Quantum Biopharma Ltd.股票行情,Quantum Biopharma Ltd.股价,Quantum Biopharma Ltd.股市,Quantum Biopharma Ltd.股票价格,Quantum Biopharma Ltd.股票交易,Quantum Biopharma Ltd.股票购买,Quantum Biopharma Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Quantum Biopharma Ltd.(QNTM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Quantum Biopharma Ltd.(QNTM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction